UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 27, 2006
|
HAEMONETICS CORPORATION |
|
|
|
(Exact name of registrant as specified in its charter) |
|
Massachusetts |
|
1-10730 |
|
04-2882273 |
|
|
|
|
|
|
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
400 Wood Road |
|
02184 |
|
|
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code 781-848-7100
|
|
|
|
|
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
Item 5.02b Departure of Director
On October 27, 2006, Ronald A. Matricaria, Chairman of the Board of Directors (the Board), notified the Board of his decision to retire from the Board at the end of the calendar year. Mr. Matricaria noted that his decision was for personal reasons and not due to any disagreement with the Company on any matter related to the Company’s operations, policies or practices.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit 99.1 – The Company’s press release dated October 31, 2006
###
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION |
|
|
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
Date: October 31, 2006 |
/s/ Ronald J. Ryan |
|
|
|
|
|
Ronald J. Ryan, Vice President and |
3
Exhibit 99.1
Haemonetics(R) Announces Change to Board of Directors
BRAINTREE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today the decision by Ronald A. Matricaria, Chairman of the Board, to retire from Haemonetics at the end of the calendar year, in order to spend more personal and professional time on the west coast. Ron Gelbman, a Haemonetics board member since 2000, was elected lead director, effective immediately.
Mr. Matricaria had been a Haemonetics director since October 2002, and chairman since April 2003.
Mr. Matricaria said, “During the past four years Haemonetics made remarkable progress in preparing to transition into a higher growth profile company. That transformation is now well underway. I am proud of my association with the Company, its employees and my colleagues on the board. There is an exciting future in store for this business.”
Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics’ products and markets, visit its web site at http://www.haemonetics.com.
|
|
CONTACT: |
|
|
Julie Fallon |
|
|
Tel. (781) 356-9517 |
|
|
Alternate Tel. (617) 320-2401 |
|
|
fallon@haemonetics.com |
SOURCE Haemonetics
Corporation
-0- 10/31/2006
/CONTACT:
Julie Fallon, +1-781-356-9517, +1-617-320-2401, fallon@haemonetics.com /
/Web site:
http://www.haemonetics.com /